BioRestorative Therapies Inc (BRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.96M
Last updated: Nov 17, 2026 at 4:10 PM ET
BioRestorative Therapies Inc (BRTX) Statistics
BioRestorative Therapies (BRTX) has a market cap of $1.96M. It kept -3089.55% of revenue as net income over the last 12 months. Its share count is up 112.13% from a year earlier.
Total Valuation
| Market Cap | $1.96M |
|---|---|
| Latest price (Nov 17, 2026) | $1.34 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 11, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 66.4x and 7.9x. Its year-end P/S ranged from 100.6x to 971.1x from 2020 to 2025.
| P/S Ratio | 66.4x |
|---|---|
| Forward P/S | 6.3x |
| P/B Ratio | 7.9x |
| P/TBV Ratio | 9.4x |
Price Statistics
The stock is down 94.96% over 52 weeks and trades 30.93% below its 50-day average.
| Beta (1Y) | 1.58 |
|---|---|
| 52-Week Change | -94.96% |
| 1-Month Change | -16.25% |
| 3-Month Change | -68.59% |
| 6-Month Change | -63.51% |
| 5-Year Change | -99.50% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -94.96% |
| Total Return (3Y CAGR) | -66.97% |
| Total Return (5Y CAGR) | -60.53% |
| Return vs SPY (1Y) | -106.16% |
| Max Drawdown (1Y) | -95.31% |
| Max Drawdown (3Y) | -98.06% |
| Sharpe Ratio (1Y) | -1.99 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $1.94 |
| 200-Day Average | $5.02 |
| 52-Week Range | $0.14 to $2.93 |
| RSI (14 Days) | 32.8 |
| Average Volume (20 Days) | 26.18K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.35x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 2.35x |
|---|---|
| Quick Ratio | 2.35x |
| Debt / Equity | 0.01x |
| Interest Coverage | 67.54x |
Returns and Efficiency
Return on invested capital is -289.87% and return on equity is -365.43% over the last 12 months.
| Return on Equity (ROE) | -365.43% |
|---|---|
| Return on Assets (ROA) | -238.27% |
| Return on Invested Capital (ROIC) | -289.87% |
| Asset Turnover | 0.05x |
| Receivables Turnover | 24.85x |
Scores
BRTX has an Altman Z-Score of -50.43, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -50.43 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $357.87K over the last 12 months is down 8.47% from the 12 months before.
| Revenue | $357.87K |
|---|---|
| Revenue Growth (YoY) | -8.47% |
| Gross Profit | $329.55K |
| Operating Income | -$14.23M |
| Pretax Income | -$11.06M |
| Net Income | -$11.06M |
| EBITDA | -$11.02M |
| Reported EPS (TTM) | -$2.04 |
Trailing 12 months through Mar 31, 2026.
Balance Sheet
Shareholder equity funds 65.30% of the $4.64M in total assets.
| Cash and Equivalents | $3.11M |
|---|---|
| Total Debt | $34.52K |
| Net Cash | $3.08M |
| Net Cash Per Share | $0.17 |
| Working Capital | $2.19M |
| Shareholder Equity | $3.03M |
| Book Value Per Share | $0.17 |
| Tangible Book Value | $2.51M |
| Tangible Book Per Share | $0.14 |
| Total Assets | $4.64M |
| Total Liabilities | $1.61M |
Balance sheet as of Mar 31, 2026.
Cash Flow
After $79.67K of capital spending, operating cash flow left -$11.90M of free cash flow.
| Operating Cash Flow | -$11.82M |
|---|---|
| Capital Expenditures | $79.67K |
| Free Cash Flow | -$11.90M |
| FCF Per Share | -$8.61 |
| Depreciation and Amortization | $210.60K |
Trailing 12 months through Mar 31, 2026.
Margins
The operating margin is -3975.00%.
| Gross Margin | 92.09% |
|---|---|
| Operating Margin | -3975.00% |
| Pretax Margin | -3089.55% |
| Net Margin | -3089.55% |
| EBITDA Margin | -3078.69% |
| FCF Margin | -3324.57% |
| Gross Margin (5Y Average) | 97.27% |
Growth
Revenue grew 44.27% a year over 3 years.
| Revenue Growth (3Y CAGR) | +44.27% |
|---|---|
| Revenue Growth (5Y CAGR) | +36.11% |
Dividends and Yields
BRTX does not pay a dividend.
| Buyback Yield | -26.56% |
|---|---|
| Shareholder Yield | -25.50% |
Stock Splits
The last split was a 1-for-20 reverse split on Sep 8, 2026.
| Last Split Date | Sep 8, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Peer Position
Against 3 similar companies, BRTX has the highest P/S.
P/S RatioPeer median 14.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| P/S Ratio | 66.4x vs 14.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -8.47% vs -100.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 104.21% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +104.21% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About BRTX
What is BRTX's market cap?
BioRestorative Therapies has a market cap of $1.96M.
How many shares of BRTX are outstanding?
BioRestorative Therapies has 17.73M shares outstanding. The count is up 112.13% from a year earlier.
Does BRTX pay a dividend?
No. BioRestorative Therapies does not pay a dividend.
How much debt does BRTX have?
BioRestorative Therapies has $34.52K of total debt and $3.11M of cash and equivalents, a net cash position of $3.08M.
BRTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors